| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Operating loss | -2,427 | -2,489 | -3,089 | |
| Other income, net | 408 | 257 | - | |
| Financial income (loss), net | 61,470 | 15,366 | -15,420 | |
| Interest expenses | - | 0 | - | |
| Income (loss) before tax expenses | 59,451 | 13,134 | -18,509 | |
| Tax expenses | 11,062 | -126 | 1,133 | |
| Net income (loss) | 48,389 | 13,260 | -19,642 | |
| Non-controlling interests | -6 | -28 | -23 | |
| Companys stockholders | 48,395 | 13,288 | -19,619 | |
| Basic income (loss) per share of common stock (in dollars per share) | 1.16 | 0.32 | -0.48 | |
| Diluted income (loss) per share of common stock (in dollars per share) | 1.13 | 0.31 | -0.48 | |
| Weighted average number of shares of common stock used in computing basic income per share of common stock (in shares) | 41,756,301 | 41,743,486 | 40,896,845 | |
| Weighted average number of shares of common stock used in computing diluted income per share of common stock (in shares) | 42,774,504 | 42,609,425 | 40,896,845 | |
ORAMED PHARMACEUTICALS INC. (ORMP)
ORAMED PHARMACEUTICALS INC. (ORMP)